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Sweden.Here, we report Prostaglandin A2 (PGA2) induced binding of HSP70 to a novel site on u1 SMAR1 50
UTR which stabilizes the wild type transcript and leads to subsequent increase in SMAR1 protein lev-
els. SMAR1 mediated cell cycle arrest is perturbed in PGA2-treated cells when HSP70 is knocked-
down. Contrarily HSP70, unlike SMAR1, is overexpressed in breast cancers. We demonstrate that this
is because of the inability of HSP70 to bind to the u17 SMAR1 UTR variant which is the predominant
form in breast cancers.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The regulation of mRNA stability is a critical control step in
determining the cellular mRNA level, attributed to discrete se-
quence elements and speciﬁc RNA–protein interactions [1]. Previ-
ously, we demonstrated that a tumor suppressor MAR-binding
protein Scaffold/Matrix attachment region-binding protein 1
(SMAR1) is drastically downregulated in higher grades of breast
cancer and cancer derived cell lines such as MCF-7, HBL-100, ZR
75.3 and ZR 75.1 [2]. This is partly attributed to the loss of stability
of the SMAR1 transcript. In these cell lines SMAR1 transcript with a
variant 50 UTR (u17 SMAR1) is predominant over the wild type UTR
transcript (u1 SMAR1). The u17 SMAR1 UTR lacks an 18 mer stem
and loop structure present in the 50 UTR of u1 SMAR1. This stem
and loop structure (termed as SL1) is critical for the formation of
three major nucleoprotein complexes on the 50 UTR, rendering sta-
bility to SMAR1 mRNA upon Prostaglandin A2 (PGA2) treatment
[3].
Here, we report the identiﬁcation of heat-shock protein 70
(HSP70) as one of the components of the nucleoprotein complex
binding to the 50 UTR of u1 SMAR1 transcript at a novel sequence
in SL1. This binding confers stability to u1 SMAR1 transcript uponchemical Societies. Published by E
ay).
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Ablation of HSP70 compromises PGA2 induced SMAR1 mediated
cell cycle arrest. However, this HSP70 regulated SMAR1 activity
is not observed in breast cancers. We demonstrate that this is be-
cause of the inability of HSP70 to bind to the u17 SMAR1 UTR var-
iant which is the predominant form in breast cancers.2. Materials and methods
2.1. Cell culture and transfections
All cells were maintained in DMEM supplemented with 10% FBS
(Invitrogen) in the presence of 5% CO2 at 37 C. Transfection of 1 lg
Flag SMAR1, pCMV HSP70, 100 nM HSP40, 70 or 90 siRNA (Santa
Cruz) was performed using Lipofectamine 2000 as per manufac-
turer’s instructions (Invitrogen). Semi conﬂuent MCF-7 cells were
treated with PGA2 at 30 and 70 lM concentrations in complete
medium and were harvested 24 h after PGA2 treatment. HSP siR-
NAs were transfected 24 h prior to the addition of PGA2 in case
of combinatorial treatments.
2.2. RNA pull-down assays
Two micrograms of biotin labeled transcripts were mixed with
500 lg of PGA2-treated cell lysates and streptavidin particles (BD
Pharmingen) in a binding mixture containing 250 lg of tRNA/total
cellular RNA/non-speciﬁc RNA, 1X gel shift buffer and kept on icelsevier B.V. All rights reserved.
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Fig. 1. HSP70 binds to SMAR1 50 UTR. (A) Representative gel of pull-down assay
demonstrating binding of 70 kDa protein to SMAR1 UTR after PGA2 treatment. (B)
Immunoblot analysis for HSP70 after the pull-down as indicated. (C) Coomassie
staining after RNA pull-down assays in MCF-7 cells treated as indicated.
1188 L. Pavithra et al. / FEBS Letters 584 (2010) 1187–1192for 10 min. The mixture was loaded onto lMACS column, elutes
were collected with 1% SDS-TE and processed for gel staining or
immunoblot analysis. UV crosslinking studies with puriﬁed Flag
HSP70 were performed as described earlier [3].
2.3. RNA immunoprecipitation
HSP70 antibody was conjugated to A/G beads following the
standard protocol. Lysates were prepared in polysome lysis buffer
and equal amounts mixed with beads. After 4 h incubation, DNaseI
and ProtK treatment, the supernatants were extracted with phenol
chloroform and washed with 70% ethanol. Total RNA obtained thus
was used for cDNA synthesis and RT-PCR analysis.
2.4. Immunostaining
Confocal microscopy of the treated cells was performed follow-
ing the standard protocol [3]. Tissue microarray slides were pur-
chased from Imgenex and processed as per manufacturer’s
instructions. For statistical analysis mean values of staining inten-
sities of SMAR1 and HSP70 were calculated using AMS-IMAGE Pro
software and subjected to one-way ANOVA and Spearman’s rank
correlation tests.
2.5. RNA electrophoretic mobility shift assays (rEMSAs)
Detailed description of probe preparation and rEMSA conditions
are as described earlier [3]. Sequences of wild type andmutant UTR
stem and loop sequences are detailed in Supplementary Table 1.
2.6. Transcription inhibition assays
For stability assays, Actinomycin D was added to the culture
media 24 h post PGA2 treatment or HSP70 transfection. For knock
down, 100 nM HSP70 speciﬁc siRNA was transfected 24 h prior to
PGA2 and Actinomycin D treatment. Protection assays were per-
formed using antisense u1 UTR and total RNA as described or pro-
cessed for cDNA synthesis. RT-PCRs were performed using speciﬁc
primers and conditions described earlier [3].
2.7. Peptide afﬁnity coelectrophoresis (PACE)
PACE experiments were performed as described [4]. Brieﬂy,
plugs containing different concentrations of GST-HSP70 or GST
were poured sequentially, resulting in a discrete gradient of pro-
tein concentration. Samples of 12.5 pM labeled RNAs were loaded
and gels were run at room temperature at 150 V for 6 h. Distance
traveled by the probe was measured from the interface of the gel
gradient to the middle of the spot.
2.8. RNA FISH
RNA FISH was performed using labeled u1 UTR as a probe and
hybridized overnight to cells treated with PGA2 with or without
pretreatment of HSP70 siRNA/scrambled siRNA. After different
washes with SSC buffer, cells were counterstained for DAPI and
visualized. The amount of transcript in the nucleus was deter-
mined by the intensity of the stain (DAPI masked).
2.9. Cell cycle analysis
Synchronized MCF-7 cells transfected with Flag SMAR1, HSP70
siRNA, SMAR1 siRNA were treated with 70 lM PGA2 and the cells
were harvested 36 h post-transfection and proceeded for FACS as
per the standard protocol [3]. PI stained cells were analyzed for cell
cycle proﬁles by FACS Vantage (Becton Dickinson) using Cell Quest.3. Results
3.1. Identiﬁcation of HSP70 as a component of nucleoprotein complex
Our previous study suggested the involvement of three distinct
nucleoprotein complexes in stabilizing SMAR1 transcript after
PGA2 treatment [3]. To identify the components of the complex,
we performed RNA pull-down assays employing the 18 mer consti-
tuting the stem and loop of SMAR1 50 UTR (SL1), u1 and u17 UTR
with PGA2-treated MCF-7 lysate. Both SL1 and u1 UTR showed a
strong band around 70 kDa while we could observe no such band
for u17 UTR (Fig. 1A, lanes 3–5). Subsequent mass spectrometric
analysis suggested HSP701A as a candidate protein (Supplemen-
tary Fig. 1A). Non-speciﬁcity was ruled out by using Flag SMAR1
(160–350) (Fig. 1A, lane 6). Competition assays using cold self
and non-self competitors were used to further demonstrate the
speciﬁcity of binding (Fig. 1A, lanes 7–10). Further, immunoblot
analysis of the sample ascertained that HSP70 was indeed associ-
ated with SL1 (Fig. 1B). Pull-down assays in MCF-7 cells pre-trea-
ted with HSP70 siRNA and related HSP family members HSP40
and HSP 90siRNAs showed that only the knockdown of HSP70 af-
fected the complex formation on the SL1 UTR (Fig. 1C, Supplemen-
tary Fig. 1B). UV crosslinking studies with SL1 and GST-HSP70
showed. Moreover, conservation of this binding could also be dem-
onstrated across the cell lines (Supplementary Fig. 1C).
3.2. Identiﬁcation of novel HSP70 binding sequence on SMAR1 50 UTR
Recombinant HSP70 showed a very weak binding afﬁnity to SL1
in gel shift analysis (Supplementary Fig. 2A), while UV crosslinking
Table 1
The sequence of various Mutants (M) and SL1 UTRs used in the study. The consensus
sequence derived is depicted beneath the table in bold.
L. Pavithra et al. / FEBS Letters 584 (2010) 1187–1192 1189analysis using Flag HSP70 showed a strong binding (Fig. 2A). So, we
performed PACE to identify the afﬁnity of recombinant HSP70 to
SL1. The graph shown in Fig. 2B is the plot of distance migrated
by the probe across the protein gradient that shows only a 20% re-
duced migration of SL1 even at 5 lM HSP70 protein. Contrarily,
even high stringency employed in pull-down assays did not deter
HSP70 binding to UTR. This suggests the involvement of post trans-
lational modiﬁcations or molecular matchmakers augmenting
HSP70 binding to SL1.
Various secondary structure mutants employed in pull-down
assays showed that mutations in the base of stem and loop
was detrimental to HSP70 binding in the UTR (Fig. 2C, Supple-
mentary Fig. 2B). Competition assays using these mutants fur-
ther conﬁrmed this result (Fig 2C, Supplementary Fig. 2C). We
next compared the sequences of these mutants to the wild type
SL1 to identify the exact binding sequence of HSP70 on SL1 and
identiﬁed ggucga at the base of SL1 to be the determinant of
HSP70 binding (Table 1). This is a ﬁrst time report of a novel
non-AU rich HSP70 binding site in the 50 UTR of SMAR1. How-
ever, there was no detectable HSP70 binding to this consensus
sequence alone (CS) demonstrating that the disruption of sec-
ondary structure caused by base mutations is more crucial for
HSP70 binding (Fig. 2E).
3.3. HSP70 binds to u1 UTR in vivo and regulates u1 SMAR1 expression
RNA-IP showed a speciﬁc PGA2 induced HSP70 association with
u1 UTR, similar to transient transfections of Flag SMAR1 and
HSP70, the binding of which is lost upon knock down of HSP70
but not HSP90 (Fig. 3A, lanes 5–11). Endogenous knockdown of
HSPs, however, did not have any effect (Fig. 3A, lanes 13–15).
Non-speciﬁcity was ruled out by using non-speciﬁc sera (NS)/
scrambled siRNA (Scr) (Fig. 3A, lanes 4, 16) and cDNA template
of u1 SMAR1 and total RNA from the 10% of lysate was used as a
positive control (Fig. 3A, lanes 2, 3 and 12). Also, HSP70 failed to
associate with u17 UTR both endogenously and upon PGA2 treat-
ment (Fig. 3B).
Results from RT-PCR analysis of u1 and u17 UTRs demonstrated
a 2.5-fold reduction only in the PGA2 induction of u1 form when
depleted of HSP70 compared SMAR1 overexpression or PGA2 treat-
ment (Fig. 3C, right panel versus left panel). These results were ver-D
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Fig. 2. HSP70 binds to SL1 in 50 UTR. (A) Analysis of HSP70 binding to SL1 by UV cros
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and HSP70 knockdown by using primers directed to the conserved
region of UTR that could amplify both the u1 and u17 forms (Sup-
plementary Fig. 3A).
3.4. HSP70 induced stabilization of u1 SMAR1
We observed a 2.7-fold increase in nuclear transcript upon
PGA2 treatment compared to 1.1-fold upon knock down of
HSP70, as demonstrated by RNA FISH (Fig. 4A, Supplementary
Fig. 3B). To demonstrate the role of HSP70 in SMAR1 mRNA stabil-
ity, we performed transcription inhibition studies upon various
treatments. MCF-7 cells treated with Actinomycin D alone, PGA2
alone and HSP70 siRNA alone served as controls for half-life exper-
iments. Concordant with our previous results, the half-life of u1
SMAR1 without any stimulation was 4 h (Fig. 4B). Treatment with
PGA2 alone led to a 1.2-fold increase in the transcript at 24 h and
decreased within 36 h to basal levels (Fig. 4C) while upon knock
down of HSP70, we could observe no detectable u1 transcript from
4 h (Fig. 4D). Upon transcriptional inhibition, PGA2 treatment in-
duced u1 SMAR1 transcript from 4 h, peaked at 24 h and remained
stable till 48 h (Fig. 4E). In case of HSP70 overexpression, the mRNA
induction was less (5-fold lower than PGA2 treatment at 24 h)
though stability was maintained till 48 h (Fig. 4F). In cells pre-trea-
ted with HSP70 siRNA before PGA2 treatment, the half-life was re-
duced by 8–12 h, suggesting that HSP70 might stabilize, but not
govern the splicing event leading to the formation of u1 form
(Fig. 4G). The results from transcription inhibition studies were
conﬁrmed by determining the protection of u1 transcript using
RNase protection assays with antisense u1 UTR as a probe (Supple-
mentary Fig. 4A–D).C
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Immunoﬂuorescence analysis of SMAR1 and HSP70 in cells
treated with PGA2 revealed the induction of both HSP70 andSMAR1 proteins, unlike cells pre-treated with HSP70 siRNA
(Fig. 5A). Further, immunoblot analysis of MCF-7 cells treated with
PGA2 and/or HSP70 siRNA showed that even a partial knockdown
of HSP70 resulted in a drastic down-regulation of SMAR1 (Fig. 5B).
Table 2
Table depicting the P-values for Spearman’s rank correlation (R-value) between
HSP70 and SMAR1 in different grades of breast cancers (Imgenex slides).
Grade Number of samples R-value P-value
Normal 9 0.45 0.001
MCLN 8 0.17 NS
II 19 0.33 NS
III 14 0.2 NS
L. Pavithra et al. / FEBS Letters 584 (2010) 1187–1192 1191Cell cycle analysis in MCF-7 cells treated with HSP70 siRNA
showed a loss of cell cycle arrest and some cells progressed to
apoptosis upon treatment with PGA2 in accordance with the previ-
ous reports (data on apoptosis not shown). Cells treated with
SMAR1 siRNA also showed marginal apoptosis but showed a more
pronounced S phase population. However, overexpression of Flag
SMAR1 partially rescued PGA2 mediated growth arrest mediated
after knock down of HSP70, showing that HSP70 mediated effects
could partially depend on SMAR1 (Fig. 5C).
HSP70 is an abundant protein while SMAR1 is scantily ex-
pressed in breast cancers, contrary to the current observations.
Tissue microarray of SMAR1 and HSP70 in different grades of can-
cer with matched case controls showed that in normal tissues, the
expression of HSP70 and SMAR1 positive correlated, while no sig-
niﬁcant correlation could be obtained for tumor samples of any
grade (P-values scored in one-way ANOVA; P < 0.05) as listed in
Table 2. This reafﬁrms that HSP70 could affect the stability but
not u1 regulation from pre-mRNA stage.
4. Discussion
Previous study by our group demonstrated the presence of a
variant UTR hosting SMAR1 termed as u17 SMAR1, in several
breast cancer cells and attributed this to the low transcript stability
in breast cancer derived cell lines. Interestingly, u17 SMAR1 pos-
sesses the same ORF and reads out SMAR1 protein similar to the
u1 clone [5]. SMAR1 transcript proﬁle also reveals that this form
is predominant in MCF-7 cells, contributing to almost 65% of the
observed total transcript. The half-life of the transcript with re-
spect to the two UTR forms is also different. This is attributed to
lack of a thermodynamically stable structure contributed by a min-
or stem–loop structure (SL1) in u17 form compared to the u1 form.
Interestingly, the genomic organization of SMAR1 is such that theDAPI SMAR1 HSP70
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with PGA2, transfected with HSP70 speciﬁc siRNA with or without PGA2 treatment. GAPD
or pre-treated with 100 nM of SMAR1, HSP70 siRNA or scrambled siRNA followed by 24SL1 structure comprising 18 bases is constituted by the junction
of the ﬁrst and second exons that are 23 KB apart. We hypothesize
that this splicing might be a selection mechanism in tumor cells to
evade the tumor suppressor activity of SMAR1. Accordingly, we
found that anticancer therapeutic PGA2 could induce the SMAR1
transcript by stabilizing the u1 transcript, by forming nucleopro-
tein complexes on the SL1 structure of u1 UTR. This study further
identiﬁes a novel mechanism in PGA2 induced SMAR1 mRNA sta-
bility, by binding of HSP70 to the SL1 of SMAR1 UTR (Fig. 6). The
ﬁrst evidence for HSP–RNA binding were provided by in vitro bind-
ing studies of HSP70 and HSP110 to AU rich sequences in 30 UTRs of
lymphokines and c-Myc RNAs [6]. Further characterization showed
that the N- and the C-terminal interactions are essential for this
RNA binding [7]. Though a recent study demonstrated binding of
HSP70 to 50 UTR of ENPP1 mRNA [8], our studies for the ﬁrst time
demonstrate HSP70 binding to a novel non-AU rich 50 UTR of
SMAR1. The weak binding of recombinant HSP70 protein to SMAR1
UTR and non-AU rich consensus element suggests that the binding
could be dictated by other nucleoprotein components, as observed
with Bmi-1 [9].
Interestingly, the overexpression of HSP70 alone does not in-
duce u1 SMAR1, rather it stabilizes the transcript, suggesting that
HSP70 binding to the UTR of SMAR1 occurs only after the splicing
event mediated by the yet identiﬁed components induced by PGA2Ce
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1192 L. Pavithra et al. / FEBS Letters 584 (2010) 1187–1192treatment. The endogenous knock down of HSP70 by siRNA, how-
ever, leads to a marginal decrease in the u17 form, prompting us to
hypothesize that the u17 form is derived from the degradation/
splicing of u1 form in these cells. The protein correlation proﬁles
of SMAR1 and HSP70 in different grades of breast cancer showed
that the expressions of these two proteins are in direct correlation
only in the normal tissues while there is no signiﬁcant correlation
with the progression of disease. This study for the ﬁrst time dem-
onstrates the regulation of a tumor suppressor protein SMAR1 by
HSP70, a prognostic marker for invasive cancers [10]. One explana-
tion could be that normal tissues/cells have the functional u1
SMAR1 while upon malignant transformation, u17 form lacking
the SL1 structure is predominant and HSP70 cannot bind to the
UTR. Additionally, estrogen responsiveness that has been recently
correlated to HSP70 expression [11] might have a role to play, since
u1 induction in response to PGA2 treatment is dependent on the
estrogen responsiveness of the cell line [3].
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